Anti-CD20 therapy and pregnancy outcomes in women with neuroimmunologic disorders

Takeaway

  • Rituximab and ocrelizumab could potentially be of interest for controlling disease activity in women with immunologic disorders intending on pregnancy, but more safety data are essential.

Why this matters

    To date, data from less than 200 pregnancies in women with neuroimmunologic conditions following exposure to anti-CD20 therapies have been reported, mainly concerning rituximab. It is currently recommended that women cease anti-CD20 therapy at least 6 to 12 months prior to conceiving. Recurrence or rebound of disease activity has been reported in patients discontinuing other disease-modifying therapies such as natalizumab and fingolimod, but not with anti-CD20 therapies.

International Medical Press is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by International Medical Press for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, International Medical Press recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of International Medical Press or the sponsor. International Medical Press assumes no liability for any material contained herein.